AtaiBeckley Inc. Common Stock — Quarterly Financial Statements (NASDAQ:ATAI)

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Market Capitalization 1.41 B
Employee 99
Founded 2018
CEO Florian Brand
Website www.ataibeckley.com
Headquarter Delaware, United States
FIGI BBG0107FR3K9
Industry Biotechnology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

AtaiBeckley Inc. - Common Stock

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.